Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~32 mi. (Lyon, France, +140 more cities)
facility
Hopital de la Croix-Rousse ( Site 0193)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~32 mi. (Lyon, France, +159 more cities)
facility
Centre Leon Berard ( Site 0465)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~32 mi. (Lyon, France, +127 more cities)
facility
Centre Leon Berard ( Site 1901)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~32 mi. (Lyon, France, +105 more cities)
facility
Centre Leon Berard ( Site 0459)
drug
bevacizumab, +1 more drug
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
city
~32 mi. (Lyon, France, +75 more cities)
facility
Institut d'Hematologie-Oncologie Pediatrique (IHOP) ( Site 0448)
drug
bleomycin, +9 more drugs
drug type
chemotherapy, +2 more types